by Brooke Salkoff for China Business Review

For Alex Gruzen, CEO of wireless charging pioneer WiTricity, working with a tech-focused venture capital firm in China seemed a natural fit. Gruzen knew China well from his time at Compaq, Hewlett-Packard, and then Dell, where he led the company’s global notebook business. Since joining Boston-based WiTricity, Gruzen’s priorities included getting the tech right, growing the US customer base, and then breaking out in China, where the automotive and consumer electronics industries – the company’s primary targets for licensing and embedding its technology – have seen meteoric growth.

The Chinese investor in this case was Haiyin Capital, a Beijing-based venture firm deploying its third fund with a new cross-border focus. Yuquan Wang, Haiyin’s founding partner, had experience partnering with American firms; early on in his career as a consultant for US consulting firm Frost & Sullivan, he helped China Mobile grow to become by market cap the largest mobile telecom company in the world. With a decade of venture capital experience, Wang had a profound appreciation for the potential of untapped synergies in the Chinese and US tech worlds.

“The next Steve Jobs won’t come from China,” Wang noted, referring to Apple’s former CEO. “But he’ll need China if he expects to build a global company. Our idea is to find those companies in the US and help them use China to achieve explosive growth.”

To read the complete article click here.

by Garrett Black for PitchBook

Chinese investment in the U.S. venture market has been exploding like fireworks over the past couple years. The number of rounds U.S. companies raised with participation from China-based investors tripled from 67 in 2012 to 201 last year. In that same timeframe, the total deal value surged from $1 billion to $4.3 billion.


To read the full article click here.

by Mike Walter of CCTV-America

Economic ties are one of the mainstays of the relationship between China and the United States. A research group in New York recently reported that since the year 2000, Chinese companies have invested 46 billion dollars in the U.S. CCTV’s Mike Walter filed this report from Los Angeles.

As part of a three-city stop aimed at highlighting opportunities for U.S. and Chinese cooperation in tech investment, Haiyin Capital coordinated an appearance by four companies on the popular CCTV show "Dialogue."  This episode included Silicon Valley investors Reid Hoffman (LinkedIn) and Peter Thiel (PayPal), who along with a live audience at Qinghua University heard from Wicab CTO Rich Hogle, Hanson Robotics founder David Hanson, LightSail Energy Chief Scientist Danielle Fong, and WiTricity CEO Alex Gruzen.

To see the episode in full click here.

by Benjamin Shobert, contributor to Forbes

Nestled in a quiet industrial park in Redmond, Washington, not too far from the Microsoft headquarters, is a small biotech start-up with both an interesting technology they are bringing to market, as well as a capital partner that suggests some ways in which global biotech research, venture capital and commercialization are going to change.

The company is Cerevast Therapeutics, the manufacturer of a non-invasive medical device that treats acute ischemic stroke through the use of acoustic energy delivered from a device the patient wears on their head immediately after they get to a stroke center and begin the IV delivery of blood-clot dissolving medicine. The device utilizes sixteen ultrasound transducers that project localized energy into the brain to disrupt blood clots where acute ischemic strokes occur through a process known as sonothrombolysis.

Founded in 2009, Cerevast recently announced that they had successfully passed the first interim analysis of their global phase 3 trial. This was certainly an important milestone for the company, but as Cerevast CEO Brad Zakes shared with me, the story behind the company’s Series C venture capital funding is also an interesting story. While Brad was out raising money, he was contacted by Haiyin Capital, a Chinese venture capital firm, who expressed a strong interest in learning more about Cerevast. This interest translated into a $5 million investment by Haiyin. While the amount was important, the ease with which Haiyin and Cerevast were able to come to terms was a breath of fresh air.

Click here to read the full article.